Currently, there are 227.17M common shares owned by the public and among those 226.11M shares have been available to trade.
The company’s stock has a 5-day price change of -15.83% and -1.68% over the past three months. ADAP shares are trading 47.54% year to date (YTD), with the 12-month market performance up to 32.80% higher. It has a 12-month low price of $0.42 and touched a high of $2.05 over the same period. ADAP has an average intraday trading volume of 1.75 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.57%, 6.33%, and 17.35% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) shares accounts for 51.66% of the company’s 227.17M shares outstanding.
It has a market capitalization of $298.93M and a beta (3y monthly) value of 2.22. The earnings-per-share (ttm) stands at -$0.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.45% over the week and 10.74% over the month.
Earnings per share for the fiscal year are expected to decrease by -650.54%, and -0.45% over the next financial year. EPS should shrink at an annualized rate of 1.00% over the next five years, compared to 10.30% over the past 5-year period.
Looking at the support for the ADAP, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on July 30, 2024, with the firm’s price target at $4. Scotiabank coverage for the Adaptimmune Therapeutics Plc ADR (ADAP) stock in a research note released on May 30, 2024 offered a Sector Outperform rating with a price target of $3.15. Bryan Garnier was of a view on March 24, 2023 that the stock is Buy, while Guggenheim gave the stock Buy rating on January 03, 2023, issuing a price target of $5. Mizuho on their part issued Buy rating on November 09, 2022.
